Vascularized organ allografts are rapidly destroyed by host immune cells that are recruited along chemokine gradients. Among chemokines, Regulated on Activation, Normal T-cell Expressed and Secreted (RANTES) CC chemokine ligand (CCL5) and monocyte chemoattractant protein (MCP)-1 (CCL2) are upregulated in rejecting cardiac allografts. To antagonize these chemokines, we constructed adenoviral vectors expressing NH 2 -terminal deletion (8ND) mutants of the respective genes. Using the F344-to-LEW rat model, intragraft gene transfer of chemokine analogs prolonged cardiac allograft survival from 10.170.7 and 10.470.7 days using non-coding adenovirus and vehicle alone, respectively, to 17.070.7 days for 8ND-RANTES (Po0.001) and 14.270.8 days for 8ND-MCP-1 (Po0.01). 8ND-RANTES reduced graft infiltration by monocytes/macrophages, cluster of differentiation (CD) 8a + and T-cell receptor ab + cells, while 8ND-MCP-1 reduced monocytes/macrophages. In mixed leukocyte reactions in vitro, proliferation of host lymphocytes from regional lymph nodes in response to donor splenocytes was unaffected by 8ND-RANTES gene transfer. Using a twogene approach, the contribution of 8ND-MCP-1 was negligible, consistent with available evidence that 8ND-RANTES inhibits both RANTES and MCP-1 activities. 8ND-RANTES gene transfer and a short course of low-dose cyclosporine A synergistically prolonged graft survival to 37.875.5 vs 15.470.5 days with cyclosporine alone (Po0.001). These results suggest a role for anti-chemokine gene therapy as an adjuvant therapy in heart transplantation. Gene Therapy (2006) and a stimulator for endothelial T-cell adhesion and proliferation. 14 Mice deficient in the RANTES gene show impaired recruitment of T cells and monocytes to inflammatory foci.
Chemokines are chemoattractant cytokines that regulate leukocyte trafficking in inflammatory conditions. 1 Acute rejection of cardiac allografts is preceded by upregulation of multiple chemokines and graft infiltration by chemokine receptor-bearing host leukocytes. 2 Regulated on Activation, Normal T-cell Expressed and Secreted (RANTES) and monocyte chemoattractant protein (MCP)-1 are members of the b-subfamily (CC) of chemokines. They are referred to as CC chemokine ligands (CCL5) and CCL2, respectively, according to the chemokine nomenclature. RANTES and MCP-1 are upregulated in cardiac allografts early after transplantation. 3, 4 RANTES is expressed by several cell types, including T cells, 5 macrophages, 6 fibroblasts 7 and endothelial cells. 8 It binds to multiple CC chemokine receptors, including CCR1, CCR3 and CCR5. 1, 9 Regulated on Activation, Normal T-cell Expressed and Secreted is a potent chemoattractant for monocytes, 10 T cells, 10 eosinophils, 11 natural killer (NK) cells 12 and dendritic cells, 13 and a stimulator for endothelial T-cell adhesion and proliferation. 14 Mice deficient in the RANTES gene show impaired recruitment of T cells and monocytes to inflammatory foci. 15 RANTES mRNA and protein are detectable in allogeneic, but not syngeneic, rat cardiac grafts around day 6 post-transplant. 3 CCR1 and CCR5 are upregulated in rejecting allografts. 2 Mice deficient in the CCR1 or CCR5 gene accept MHC class I-mismatched cardiac allografts for prolonged periods of time, and MHC class II-mismatched grafts in the long term. 16, 17 In humans, RANTES + cells were identified within cellular infiltrates in 95% of endomyocardial biopsies with moderate/severe graft rejection, and 28% with mild rejection. 18 Homozygozity for the CCR5-D32 gene variant that results in inactive CCR5 has been associated with improved graft survival after kidney transplantation. 19 These findings suggest an important role for RANTES in graft rejection.
Monocyte chemoattractant protein-1 is a potent chemoattractant for monocytes and a stimulator of monocyte adhesion to the endothelium. 20 Mice deficient in the MCP-1 gene show abnormal monocyte recruitment to inflammatory foci and cytokine expression. 21 Monocyte chemoattractant protein-1 is upregulated in rat and human cardiac allografts early after transplantation. 4, 22, 23 We have constructed adenoviral (Ad) vectors expressing NH 2 -terminal deletion (ND) mutants of the human RANTES and MCP-1 genes. The RANTES (9-68) and the MCP-1 (9-76) analogs lacking the first eight NH 2 -terminal residues (8ND) have been shown to block signaling by the corresponding chemokines with high efficacy, in the absence of relevant receptor activation. 9 Although native RANTES was specific for RANTES binding sites, 8ND-RANTES strongly antagonized multiple different chemokines, including RANTES, MCP-1 and MCP-3. Conversely, 8ND-MCP-1 inhibited the activities induced by MCP-1 and MCP-3, but not RANTES.
We have evaluated the therapeutic efficacy of Ad vectors expressing 8ND-RANTES or 8ND-MCP-1 in the allogeneic F344-to-Lewis (LEW) rat heart transplantation model. The gene transfer protocol was first established using an Ad-LacZ reporter vector instilled into the coronary arteries of donor hearts that were subsequently placed in the abdominal position in the hosts. 24 8ND-RANTES and 8ND-MCP-1 protein expression was detectable by enzyme-linked immunosorbent assay (ELISA) 25 in 293-cells preincubated with the corresponding vectors in vitro (E1.3 and 8.3 ng/ml, respectively). In cardiac allografts, 8ND-RANTES mRNA expression was detectable by real-time reverse transcriptase (RT)-polymerase chain reaction (PCR) at day 6 post-transplant (median DC T value: À3.7; range: À2.6 to À3.8). Intragraft 8ND-RANTES protein expression was detectable by immunostaining ( Figure 1a ) and ELISA (E80 pg/ml). Circulating 8ND-RANTES levels were detectable by ELISA (E15-30 pg/ml) 6 days after 8ND-RANTES gene transfer, but not after administration of a non-coding adenovector (Ad-Null). Circulating 8ND-MCP-1 levels were detectable by ELISA (E50-3000 pg/ml) after 8ND-MCP-1 gene transfer, but not using Ad-Null.
Survival of grafts receiving Ad-Null or virus storage buffer diluted in phosphate-buffered saline (PBS) was 10.170.7 and 10.470.7 days, respectively (Figure 1b These findings indicate that intragraft expression of RANTES and, to a lesser extent, MCP-1 analogs reduces graft infiltration by leukocytes and delays cardiac allograft rejection in a rat model. Using a two-gene approach, the effect of 8ND-MCP-1 was negligible. This result is consistent with previous in vitro data showing that 8ND-RANTES potently inhibits multiple different chemokines, including RANTES itself, MCP-1 and MCP-3. 9 Another possible explanation relates to clinical data suggesting that RANTES may play a more prominent role than MCP-1 in graft rejection. Indeed, while both chemokines were upregulated in endomyocardial biopsies from patients in the first year post-transplant, only RANTES expression was correlated with graft rejection. 26 8ND-MCP-1 gene transfer reduced graft infiltration by monocytes/macrophages, but not T cells. These inhibitory effects on graftinfiltrating leukocytes correspond to the profiles of chemotactic activities of RANTES on monocytes, 10 T cells 10 and NK cells, 12 while MCP-1 attracts monocytes. 20 RANTES also stimulates T-cell adhesion and proliferation, 14 as well as activation of immature dendritic cells and their subsequent migration. 27 In the present study, 8ND-RANTES gene transfer significantly reduced IL-1b expression in cardiac allografts. Interleukin-1b is strongly 
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S Fleury et al upregulated as a result of ischemia-reperfusion injury. It promotes a destructive inflammation through activation of macrophages and T cells, potentially causing primary failure in cardiac isografts. 28 Finally, introduction of the 8ND-RANTES gene into the donor heart did not affect levels of alloreactive T-cell priming to the allograft, as assessed in mixed leukocyte reactions in vitro. These findings suggest that the RANTES analog acts predominantly by shaping the graft's microenvironment.
Graft protection by 8ND-RANTES was not further improved by increasing the virus dosage from 10 10 to 5 Â 10 10 PFU. This was presumably due to a dosedependent increase in viral toxicity. Similarly, repeated adenovirus administration was not useful, consistent with previous evidence that anti-Ad immune responses prevent vector readministration, 29 and also due to repeated surgical trauma. Most importantly, however, 8ND-RANTES gene transfer and subtherapeutic doses of cyclosporine A during 5 days synergistically prolonged graft survival.
Our results are in good agreement with a previous study using vMIP-II and MC148, two chemokine homologs encoded by human herpes virus 8 and Molluscum contagiosum, respectively, which block multiple CC and CXC chemokine receptors. 30 Vascularized mouse cardiac allografts transfected with vMIP-II or MC148 survived slightly longer than untreated grafts (10.570.5 and 10.870.5 days vs 8.170.3 days, respectively; Po0.001). This effect was not associated with changes in systemic donor-specific immune responses. Our results are also concordant with non-gene transfer-based approaches using different RANTES or CCR1 antagonists in transplant models. Anti-RANTES serum prolonged cardiac allograft survival in rats.
3 BX471, a non-peptide CCR1 antagonist, prolonged heart (17.575.9 vs 7.370.5 days) and kidney (16.972.1 vs 12.371.7 days) transplant survival in rats and rabbits, respectively. 31, 32 Met-RANTES facilitated rat kidney and bowel allograft acceptance. 33, 34 In line with these reports, 8ND-RANTES delayed graft rejection, but ultimately failed to prevent it. This is presumably due to the promiscuous receptorligand-binding affinities and functional redundancy in the chemokine system. 1 Also, chemokine inhibition does not primarily target T-cell activation. Nevertheless, CCR1-or CCR5-deficient mice accepted cardiac allografts for extended periods of time, 16, 17 which supports the notion that thorough suppression of a single chemokine receptor can profoundly affect rejection. In a clinical setting, introduction of a protective gene into the donor heart would be performed in solution immediately following organ procurement before reperfusion. Organ protection during procurement and transportation involves hypothermic conditions (cold ischemia). Adenovirus internalization and subsequent entry into the target cell is an energy-dependent process that is most efficient under normothermic conditions. 35 Nevertheless, adenovirus-mediated gene transfer into rat donor hearts under hypothermic conditions can be enhanced by means of an ex vivo perfusion system. 36 Similar results have been reported using adeno-associated virus vectors and an ex vivo recirculation system in rat cardiac isografts. 37 Hypothermic continuous coronary microperfusion with oxygenated University of Wisconsin solution has been shown to effectively preserve rabbit donor hearts for 24 h. 38 An important area of current research is the compatibility between gene delivery vehicles and organ preservation solutions.
Further studies are needed to optimize anti-chemokine gene therapy. The synergistic effect observed with 8ND-RANTES gene transfer combined with five subtheraputic doses of cyclosporine A suggests a potential role for chemokine inhibition as an adjuvant therapy in transplantation.
Materials and methods

Adenoviral vectors
Human Regulated on Activation, Normal T-cell Expressed and Secreted (RANTES) and human MCP-1 complementary DNAs (cDNAs) were provided by Etienne Régulier (Lausanne, Switzerland). 8ND-RANTES and 8ND-MCP-1 cDNAs were obtained by PCR-based site-directed deletion by overlap extension. After sequencing, they were placed separately in a CMV promoter-driven expression cassette in the pcDNA3.1/A vector. Recombinant Ad-8ND-RANTES and Ad-8ND-MCP-1 were generated as described. 25 Ad-BHG3 containing no transgene (Ad-Null) was used as a control. Concentrated virus stocks were prepared using three CsCl 2 ultracentrifugation gradients and stored in storage buffer (10 mmol/l Tris-HCl, pH 7.4, 1 mmol/l MgCl 2 , 3% sucrose). Titers of Ad-8ND-RANTES, Ad-8ND-MCP-1 and Ad-Null stock solutions by plaque assay on 293 cells were 2 Â 10 11 , 6Â 10 10 and 3 Â 10 11 PFU/ml, respectively (virus/infectious particle-ratio E5-20). As a control infusate, virus storage buffer was diluted in PBS (pH 7.4) in the same proportions as was done for the virus stock.
Gene transfer and heart transplantation
Surgical procedures were performed in accordance with the guidelines for animal experimentation at our institution. Male F344 and LEW rats (8-12 weeks old; from IFFA-CREDO, L'Arbresle, France) were used as graft donors and recipients, respectively. After intracoronary infusion of vector-containing solution (E10 10 PFU virus diluted in PBS, at RT, to a final volume of 600 ml), the donor heart was immediately immerged in ice-cold PBS and transplanted 15 min later. In a separate series of experiments, donor hearts received 5 Â 10 10 PFU Ad-8ND-RANTES. Repeated intragraft Ad-8ND-RANTES administration was performed at days 0 and 7 posttransplant, together with CsA administration (1.5 mg/ Cardiac allograft survival S Fleury et al kg/day intramuscular) from day À1 to day 3 post-transplant. In a separate series of experiments, donor hearts received a single Ad-8ND-RANTES dose at the time of transplantation combined with CsA, or CsA alone. Grafts were placed in the abdominal position and graft survival was monitored by daily palpation. Rejection, defined as total cessation of heart beating, was confirmed by direct graft examination.
Detection of transgene expression
Intragraft 8ND-RANTES mRNA expression was analyzed by real-time RT-PCR (n ¼ 4). 8ND-RANTES protein expression was tested by immunostaining using goat anti-human RANTES antibody (C-19; Santa Cruz Biotechnology, sc-1410), followed by biotin-conjugated rabbit anti-goat IgG, StreptABComplex/horseradish peroxidase (HRP) and nickel-diaminobenzidene (DAB)/ H 2 O 2 (Dako). 8ND-RANTES protein levels were measured in 293 cells preincubated with Ad-8ND-RANTES (MOIE2; 40 h) in vitro, as well as in cardiac allografts and plasma at day 6 post-transplant using a human RANTES ELISA kit (Biosource). 8ND-MCP-1 was measured using a human MCP-1 ELISA kit (Biosource) that does not react with endogenous MCP-1. 25 
Immunostaining of inflammatory cell infiltrates
Immunohistology was performed on cryostat sections of allografts excised at day 6 post-transplant. Four series of sections per heart (n ¼ 4/group) were cut at 500-mm steps from the apex to the basis and stained using the following mouse antibodies: anti-ED1-like (1C7), antiTCRab (R73), anti-CD8a (OX-8; all from PharMingen, San Jose, CA, USA) and anti-CD4 (W3/25; Accurate Chemicals, Westbury, NY, USA); irrelevant mouse antiboby (MOPC-31C; PharMingen) was used as a control. Detection steps were biotin-conjugated rabbit F(ab 0 ) 2 anti-mouse Ig (Jackson ImmunoResearch, West Grove, PA, USA), followed by StreptABComplex/HRP and DAB/H 2 O 2 . Images were acquired by a Hyper-HADAxioscop microscope, Axiocam-MRcD system (Carl Zeiss, Jena, Germany). Morphometric analysis was performed in four microscopic fields ( Â 100) per heart section using the NIH-Image-1.62 program. Positivestaining surface area for each cellular marker was normalized to total myocardial surface area.
Real-time reverse transcriptase-polymerase chain reaction for inflammatory cytokines Hearts (n ¼ 4/group) were excised at day 6 posttransplant and B300 mg tissue was placed in ice-cold RNAlater Stabilization Reagent. Total RNA was extracted using the Qiagen RNeasy kit. Complementary DNA was generated from DNase-treated RNA using Omniscript RT (Qiagen, Venlo, The Netherlands), random hexamer (Promega, Madison, WI, USA) and RNase inhibitor (Roche, Basel, Switzerland). Cytokine transcripts were determined by Rotor-gene multifilter real-time cycler (Corbett Research). Hypoxanthine phosphoribosyltransferase (HPRT) was used as an endogenous control to correct for variations in RNA loading or amplification reaction efficiency. Primer sequences were as follows:
interferon-g (IFN-g) The threshold cycle (C T ) is the fractional cycle number at which the reported fluorescence reaches a predefined level. Target gene normalized to HPRT expression is shown as DC T ( ¼ C T of target gene minus C T of HPRT).
Mixed leukocyte reactions
Lymphocytes and splenocytes were collected from mesenteric lymph nodes and spleen, respectively. Singlecell suspensions were obtained using a 70-mm strainer. Splenocytes were washed once in PBS, resuspended in 5 ml ACK cell lysing buffer (cat. number 10-548E; Cambrex BioScience, Walkersville, MD, USA, 5 min; RT), and irradiated with 1000 rad. Lymphocytes and splenocytes were washed once and resuspended in RPMI, 10%-fetal bovine serum, penicillin/streptomycin and 50 mM 2-mercaptoethanol at a density of 2.5 Â 10 6 cells/ml. Mixed lymphocyte/splenocyte (1:1-ratio) cultures were placed in 96-well-plates (U-bottomed) using eight wells for each experimental condition. After 5 days, 1 mCi 3 Hthymidine/well was added, and plates were read 18 h later using a b-counter (TopCount NXT; PerkinElmer, Wellesley, MA, USA).
Statistical analysis
Graft survival data, shown as the mean values7s.e. and as Kaplan-Meier cumulative survival curves, were analyzed by log-rank test (JMP program, version 5; SAS Institute). Immunohistological and RT-PCR data, reported as the median value (range), were analyzed by Mann-Whitney U-test using a significance level of Po0.05.
